Abstract
Despite their obvious structural dissimilarities, the cannabinoids and aminoalkylindoles (AAIs) are known to exhibit similar in vitro and in vivo cannabimimetic activities1–6. This body of evidence suggests that the cannabinoids and AAIs interact with the same cannabinoid receptor and share at least some regions in common when bound to the receptor to elicit the cannabinoid activity. In support of this hypothesis, binding studies have shown that they compete for the same binding regions of the CB1 cannabinoid receptor7.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
S. J. Ward, E. Baizman, M. Bell, S. Childers, T. D’Ambra, M. Eissenstat, K. Estep, D. Haycock, A. Howlett, D. Luttinger, M. Miller, and M. Pacheco, In Problems of Drug Dependence; Harris, L. S., Ed.; NIDA Research Monograph, National Institute on Drug Abuse: Rockville, MD, 425 (1990).
C. C. Felder, J. S. Veluz, H. L. Williams, E. M. Briley, and L. Matsuda, Mol. Pharmacol. 42: 838 (1993).
A. C. Howlett, B. Berglund, and L. S. Melvin, Curr. Pharmaceut. Des. 1: 343 (1995).
R. Mechoulam, A. Breuer, R. U. C. Jarbe, A. J. Hiltunen, and R. Glaser, J. Med. Chem. 33: 1037 (1990).
B. R. Martin, D. R. Compton, B. F. Thomas, W. R. Prescott, P. J. Little, R. K. Razdan, M. R. Johnson, L. S. Melvin, R. Mechoulam, and S. J. Ward, Pharmacol. Biochem. Behay. 40: 471 (1991).
J. E. Kuster, J. I. Stevenson, S. J. Ward, T. E. D’Ambra, and D. A. Haycock, J. Pharmacol. Exp. Ther. 264: 1352 (1993).
K. Yamada, K. C. Rice, J. L. Flippen-Anderson, M. A. Eissenstat, S. J. Ward, M. R. Johnson, and A. C. Howlett, J. Med. Chem. 39: 1967 (1996).
R. K. Razdan Pharmacol. Rev. 38: 75 (1986).
L. S. Melvin and M. R. Johnson, In Structure-Activity Relationships of the Cannabinoids; NIDA Research Monograph 79; National Institute on Drug Abuse: Rockville, MD; 31 (1987).
L. S. Melvin, G. M. Milne, M. R. Johnson, B. Subramaniam, G. H. Wilken, and A. C. Howlett, Mol. Pharmacol. 44: 1008 (1993).
L. S. Melvin, G. M. Milne, M. R. Johnson, G. H. Wilken, and A. C. Howlett, Drug Design and Discovery 13: 155 (1995).
M. A. Eissenstat, M. R. Bell, T. E. D’Ambra, E. J. Alexander, S. J. Daum, J. H. Ackerman, M. D. Gruett, V. Kumar, K. G. Estep, E. M. Olefirowicz, J. R. Wetzel, M. D. Alexander, J. D. Weaver, III, D. A. Haycock, D. A. Luttinger, F. M. Casiano, S. M. Chippari, J. E. Kuster, J. I. Stevenson, and S. J. Ward, J. Med. Chem. 38: 3094 (1995).
T. E. D’Ambra, K. G. Estep, M. R. Bell, M. A. Eissenstat, K. A. Josef, S. J. Ward, D. A. Haycock, E. R. Baizman, F. M. Casiano, N. C. Beglin, S. M. Chippari, J. D. Grego, R. K. Kullnig, and G. T. Daley, J. Med. Chem., 35: 124 (1992).
M. R. Bell, T. E. D’Ambra, V. Kumar, M. A. Eissenstat, J. L. Herrmann, Jr., J. R. Wetzel, D. Rosi, R. E. Philion, S. J. Daum, D. J. Hlasta, R. K. Kullnig, J. H. Ackerman, D. R. Haubrich, D. A. Luttinger, E. R. Baizman, M. S. Miller, and S. J. Ward, J. Med. Chem. 34: 1099 (1991).
P. H. Reggio, K. V. Greer, and S. M. Cox, J. Med. Chem. 32: 1630 (1989).
P. H. Reggio, A. M. Panu, and S. Miles, J. Med. Chem. 36: 1761 (1993).
J. W. Huffman, D. Dai, B. R. Martin, and D R. Compton, Bioorganic A Medicinal Chem. Lett. 4: 563 (1994).
X.-Q. Xie, M. Eissenstat, and A. Makriyannis, Life Sci. 56: 1963 (1995).
J. A. H. Lainton, J. W. Huffman, B. R. Martin, and D. R. Compton, Tetrahedron Lett. 36: 1401 (1995).
W. Tong, E. R. Collantes, A. C. Howlett, and W. J. Welsh, J. Med. Chem. 41: 4207 (1998).
J. Y. Shim, E. R. Collantes, W. J. Welsh, B. Subramaniam, A. C. Howlett, M. A. Eissenstat, and S. J. Ward, J. Med. Chem. 41:4521 (1998); J.-Y. Shim, E. R. Collantes, W. J. Welsh, and A. C. Howlett, In ACS Symposium Series on Rational Drug Design,American Chemical Society (in press).
J. W. Huffman, S. Yu, V. Showalter, M. E. Abood, J. L. Wiley, D. R. Compton, B. R. Martin, R. D. Bramblett, and P. H. Reggio, J. Med. Chem. 39: 3875 (1996).
DISCO: Y. Martin, M. G. Bures, E. A. Danaher, J. DeLazzer, I. Lico, and P. A. Pavlik, J. Comp.-Aid. Mol. Des. 7:83 (1993).
The molecular modeling program Sybyl is a product of Tripos, Inc., St. Louis, MO 63144.
J. Gasteiger and M. Marsili, Tetrahedron 36: 3219 (1980).
R. S. Rapaka and A. Makriyannis, In Structure-Activity Relationships of the Cannabinoids; NIDA Research Monograph 79; National Institute on Drug Abuse: Rockville, MD (1987).
A. C. Howlett, M. R. Johnson, L. S. Melvin, and G. M. Milne, Mol. Pharmacol. 33: 297 (1988).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer Science+Business Media New York
About this chapter
Cite this chapter
Shim, JY., Collantes, E.R., Welsh, W.J., Howlett, A.C. (2000). Unified Pharmacophoric Model for Cannabinoids and Aminoalkylindoles. In: Gundertofte, K., Jørgensen, F.S. (eds) Molecular Modeling and Prediction of Bioactivity. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-4141-7_23
Download citation
DOI: https://doi.org/10.1007/978-1-4615-4141-7_23
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6857-1
Online ISBN: 978-1-4615-4141-7
eBook Packages: Springer Book Archive